前列腺癌SBRT与其他当代放疗技术的第二恶性肿瘤概率
该队列分析纳入303,432例局限性前列腺癌患者,随访至少60个月,比较根治性前列腺切除术(RP)、常规分割IMRT(CF-IMRT)、中度大分割IMRT(HF-IMRT)、近距离放疗(BT)与立体定向体部放疗(SBRT)后的第二恶性肿瘤(SM)概率。结果显示CF-IMRT、HF-IMRT和BT的SM概率均高于RP,而SBRT与RP无显著差异,且SBRT的SM概率低于CF-IMRT。
要点
- CF-IMRT、HF-IMRT和BT的SM概率显著高于RP,SBRT与RP无显著差异。
- SBRT相比CF-IMRT的SM概率更低(AOR 0.78,95%CI 0.66-0.93,P=0.005)。
- SBRT可能因适形性更好、放射生物学差异或患者选择而降低SM风险。
核心结论
- CF-IMRT、HF-IMRT和BT相比RP与第二恶性肿瘤概率增加相关,而SBRT未显示增加。
- SBRT相比CF-IMRT与更低的第二恶性肿瘤概率相关。
研究设计与样本
- 基于全国代表性数据库的队列分析,纳入303,432例局限性前列腺癌男性,随访至少60个月。
- 使用多变量逻辑模型生成预测概率,并进行倾向性评分调整的成对比较。
主要发现
- 中位随访9.08年(IQR 7.01-11.21)。
- SM预测率:RP 6.0%,CF-IMRT 7.1%,HF-IMRT 7.3%,BT 6.6%,SBRT 5.7%。
- 以RP为参照的调整比值比(AOR):CF-IMRT 1.20(95%CI 1.14-1.25,P<0.001),HF-IMRT 1.25(95%CI 1.01-1.55,P=0.045),BT 1.11(95%CI 1.07-1.16,P<0.001),SBRT 0.95(95%CI 0.81-1.12,P=0.567)。
- 倾向性评分调整分析:SBRT相比CF-IMRT的AOR 0.78(95%CI 0.66-0.93,P=0.005);SBRT相比RP的AOR 0.86(95%CI 0.73-1.03,P=0.102)。
临床怎么用
- 对于局限性前列腺癌患者,选择SBRT而非CF-IMRT、HF-IMRT或BT可能降低第二恶性肿瘤概率。
- SBRT与RP在第二恶性肿瘤概率上无显著差异,可作为讨论放疗风险时的参考。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate radiotherapy has been associated with an increased risk of developing a second malignancy (SM). However, relative SM probabilities following treatment with contemporary radiation techniques such as stereotactic body radiotherapy (SBRT) or moderately hypofractionated intensity modulated radiotherapy (HF-IMRT) remain unknown. METHODS: A cohort analysis was performed of men from a nationally representative database with localized prostate cancer with at least 60 months of follow-up comparing SM probability amongst men receiving either radical prostatectomy (RP), conventionally fractionated intensity-modulated radiotherapy (CF-IMRT), HF-IMRT, brachytherapy (BT), or SBRT, using multivariable logistic models, which were used to generate predicted probabilities. Additionally, propensity score-adjusted pairwise assessments of modalities were performed. RESULTS: For 303,432 patients included in the study, median follow-up was 9.08 years (IQR 7.01-11.21). Predicted rates of SM by treatment modality and adjusted odds ratios (AOR) for development of SM (referent: RP) were: 6.0% for RP (AOR n/a), 7.1% for CF-IMRT (AOR 1.20, 95%CI 1.14-1.25, P < 0.001), 7.3% for HF-IMRT (AOR 1.25, 95%CI 1.01-1.55, P = 0.045), 6.6% for BT (AOR 1.11, 95%CI 1.07-1.16, P < 0.001), and 5.7% for SBRT (AOR 0.95, 95%CI 0.81-1.12, P = 0.567). On propensity score-adjusted analysis, SBRT was associated with lower odds of SM compared to CF-IMRT (AOR 0.78, 95%CI 0.66-0.93, P = 0.005); no significant difference was found when SBRT was compared to RP (AOR 0.86, 95%CI 0.73-1.03, P = 0.102). CONCLUSIONS: Conventionally fractionated intensity-modulated radiotherapy, moderately hypofractionated intensity-modulated radiotherapy, and brachytherapy but not stereotactic body radiotherapy were associated with increased probability of a second malignancy compared to radical prostatectomy. Patients treated with SBRT may be at lower risk of second malignancy due to improved conformality, radiobiological differences or patient selection. The possibility that SBRT in select patients may minimize the probability of SM underscores the need for assessment of second malignancy risk in prospective studies of SBRT.
引用
- Dee EC, Muralidhar V, King MT, et al. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiother Oncol. 2021. PMID: 34171451. doi:10.1016/j.radonc.2021.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。